The role of serotonin in depression and clotting in the coronary artery disease population

Journal of Cardiovascular Nursing

Volumn 26, Issue 5, 2011, Pages 423-429

  Sanner, Jennifer E ^a   Frazier, Lorraine ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

acute coronary syndrome; coronary artery disease; depression; platelet serotonin

Indexed keywords

SEROTONIN;

BLOOD; BLOOD CLOTTING; CORONARY ARTERY DISEASE; DEPRESSION; HUMAN; PHYSIOLOGY; REVIEW;

BLOOD COAGULATION; CORONARY ARTERY DISEASE; DEPRESSION; HUMANS; SEROTONIN;

EID: 80052277298     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/JCN.0b013e3182076a81     Document Type: Review

References (48)

1. World Health Organization. The global burden of disease 2004 update. www.who.int/topics/global-burden-of-disease/en/. Accessed June 1, 2009.
2. National Health andNutrition Examination Survey. National Center for Health Statistics. 2005-2006. http://www.cdc.gov/nchs/nhanes/nhanes2005-2006/ nhanes05-06.htm. Accessed June 1, 2009.
3. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;209(7):898-904. (Pubitemid 37430461)
4. Pratt LA, Brody DJ. Depression in the United States Household Population, 2005-2006. National Center for Health Statistics. 2008;7:1-7. http://www.cdc.gov/nchs/data/databriefs/db07.htm. Accessed June 1, 2009.
5. Ellis JJ, Eagle KA, Kline-Rogers EM, Erickson SR. Depressive symptoms and treatment after acute coronary syndrome. Int J Cardiol. 2005;99:443-447. (Pubitemid 40363996)
6. Frasure-Smith N, Lesperance F, Irwin MR, Sauve C, Lesperance J, Theroux P. Depression, C-reactive protein and two-year major adverse cardiac events in men after acute coronary syndromes. Biol Psychiatry. 2007;62(4): 302-308. (Pubitemid 47444279)
7. Steptoe A, Brydon L. Emotional triggering of cardiac events. Neurosci Biobehav Rev. 2009;33(2):63-70.
8. Bush DE, Ziegelstein RC, Tayback M, et al. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. Am J Cardiol. 2001;102:1773-1779.
9. Ariyo AA, Haan M, Tangen CM, et al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. Circulation. 2000;102(15): 1773-1779.
10. Penninx BW, Beekman AT, Honig A, et al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry. 2001;58:221-227. (Pubitemid 32209674)
11. Somberg TC, Arora RR. Depression and heart disease: therapeutic implications. Cardiology. 2008;111:75-81.
12. Nestler EJ, Gould E, Manji H, et al. Preclinical models: status of basic research in depression. Biol Psychiatry. 2002; 53(3):503-528. (Pubitemid 35284020)
13. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of the supporting evidence. Am J Psychiatry. 1965;122:509-522.
14. Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry. 2000; 63:273-279.
15. Elhwuegi AS. Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:435-451. (Pubitemid 38490755)
16. Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. Can Med Assoc J. 2009; 180(3):305-313.
17. Van Praag HM. Depression, suicide and the metabolism of serotonin in the brain. J Affect Disord. 1982;4:275-290. (Pubitemid 13196491)
18. Belmaker RH, Agam G. Major depressive disorder. NEJM. 2008;358(1):55-68.
19. Meyer JH, Ginovart N, Boovariwala A, et al. Elevated monoamine oxidase A levels in the brain. An explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry. 2006;63:1209-1216. (Pubitemid 44708079)
20. NeumeisterA, Yuan P, Young TA, et al. Effects of tryptophan depletion on serum levels of brain-derived neurotrophic factor in unmedicated patients with remitted depression and health subjects. Am J Psychiatry. 2005;162:805-807. (Pubitemid 40489150)
21. Wirleitner B, Rudzite V, Neurauter G, et al. Immune activation and degradation of tryptophan in coronary artery disease. Eur J Clin Invest. 2003;33:550-554. (Pubitemid 36783213)
22. Plein H, Berk M. The platelet as a peripheral marker in psychiatric illness. Hum Psychopharmacol. 2001;16: 229-236. (Pubitemid 32421889)
23. Cote F, Fligny C, Fromes Y, Mallet J, Vodjdani G. Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol Med. 2004;10(5):232-238. (Pubitemid 38581796)
24. Markovitz JH, Matthews KA. Platelets and coronary heart disease: potential psychophysiologic mechanisms. Psychosom Med. 1991;53:643-688.
25. Watts SW. The love of a lifetime: 5-HT in the cardiovascular system. Am J Physiol Regul Integer Comp Physiol. 2009;263(2):R252-R256.
26. Kihara H, Hirose K, Koganei H, et al. AT-1015, a novel serotonin (5-HT) 2 receptor antagonist, blocks vascular and platelet 5-HT2A receptors and prevents the laurateinduced peripheral vascular lesion in rats. J Cardiovasc Pharmacol. 2000;35(4):523-530. (Pubitemid 30185450)
27. Serebruany VL, Glassman AH, Malinin AI, et al. Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials. Blood Coagul Fibrinolysis. 2003;14:563-567. (Pubitemid 37083172)
28. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481-3488. (Pubitemid 40923403)
29. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006; 47(8, supplement C):C13-C18.
30. Mendelson SD. The current status of the platelet 5-HT (2A) receptor in depression. J Affect Disord. 2000;27(1-3):13-24. (Pubitemid 30119953)
31. Choi SY, Mintz GS. What we have learned about plaque rupture in acute coronary syndromes? Curr Cardiol Rep. 2010;12(4):338-343.
32. Pakala R, Willerson JT, Benedict CR. Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation. 1997; 96(7):2280-2286. (Pubitemid 27425834)
33. Willerson JT, Eidt JF,McNatt J, et al. Role of thromboxane and serotonin as mediators in the development of spontaneous alterations in coronary blood flow and neointimal proliferation in canine models with chronic coronary artery stenoses and endothelial injury. J Am Coll Cardiol. 1991; 17(6 suppl B):101B-110B.
34. Fleming JS, Buchanan JO, Yocca FD, Iben LG, Antonaccio MJ. Effect of encainide, ODE, MODE, and flecainide on ADP/5-HT induced platelet aggregation and in the anesthetized dog coronary artery stenosisYocclusion model of intravascular thrombosis. Cardiovasc Drugs Ther. 1991;5(4): 763-768.
35. Parakh K, Sakhuja A, Bhat U, Ziegelstein RC. Platelet function in patients with depression. South Med J. 2008;101(6): 612-617.
36. Bruce EC,Musselman DL. Depression, alterations in platelet function, and ischemic heart disease. Psychosom Med. 2005; 67(supplement 1):S34-S36.
37. Von Kanel R. Platelet hyperactivity in clinical depression and the beneficial effect of antidepressant drug treatment: how strong is the evidence? Acta Psychiatr Scand. 2004;110: 163-177. (Pubitemid 39120319)
38. Schins A, Honig A, Crijns H, Baur L, Hamulyak K. Increased coronary events in depressed cardiovascular patients: 5-HT2A receptor as missing link? Psychosom Med. 2003;65: 729-737. (Pubitemid 37163376)
39. Shimbo D, Child J, Davidson K, et al. Exaggerated serotoninmediated platelet reactivity as a possible link in depression and acute coronary syndrome. Am J Cardiol. 2002;89: 331-333. (Pubitemid 34113797)
40. Franke L, Schewe HJ, Muller B, et al. Serotonergic platelet variables in unmediated patients suffering from major depression and healthy subjects: relationship between 5HT content and 5HT uptake. Life Sci. 2000;67:301-305.
41. Muck-Seler D, Pivac N, Mustapic M, et al. Platelet serotonin and plasma prolactin and cortisol in healthy, depressed, and schizophrenic women. Psychiatry Res. 2004; 127:217-226. (Pubitemid 39024499)
42. Vikenes K, Farstad M, Nordrehaug JE. Serotonin is associated with coronary artery disease and cardiac events. Circulation. 1999;100:483-489. (Pubitemid 29360156)
43. Schins A, Hamulyak K, Scharpe S, et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sci. 2004;76(6):637-650. (Pubitemid 39573394)
44. van den Brink RHS, van Melle J, Honig A, et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial Infarction and Depression-Intervention Trial (MIND-IT). Am Heart J. 2002;144:219-225. (Pubitemid 34879642)
45. Wulsin LR, Musselman D, Otte C, Bruce E, Ali S, Whooley MA. Depression and whole blood serotonin in patients with coronary heart disease from the Heart and Soul Study. Psychosom Med. 2009;71(3):260-265.
46. Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, Whooley MA. Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA. 2003;290(18): 215-221. (Pubitemid 37430060)
47. Blouin AG, Perez EL, Blouin JH. Computerized administration of the diagnostic interview schedule. Psychiatry Res. 1988;23(3):335-344.
48. Spitzer RL, Kroenke K, Williams JBW. Validation and utility of a self-report version of the PRIME-MD: the PHQ primary care study. JAMA. 1999;282(18):1737-1744. (Pubitemid 29533604)